Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.35 |
| ▸ | GLS | O94925 | 1/20 | 0.35 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | RORA | P35398 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | RORB | Q92753 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26777096 | 0.85 | HTR2A (0.39) | HTR2AHTR2CNR3C1KCNH2CYP11B1 | |
| SCHEMBL26270853 | 0.81 | HTR2A (0.52) | HTR2AHTR2CNR3C1KCNH2CYP11B1 | |
| SCHEMBL4434459 | 0.81 | KMO (0.42) | KMOCACNA1HTRPM8 | |
| SCHEMBL13483882 | 0.80 | KMO (0.38) | HTR2AHTR2CNR3C1KCNH2CYP11B1 | |
| SCHEMBL26270865 | 0.80 | HTR2A (0.51) | HTR2AHTR2CNR3C1KCNH2CYP11B1 | |
| SCHEMBL13483881 | 0.80 | MAOB (0.49) | HTR2AHTR2CNR3C1KCNH2CYP11B1 | |
| SCHEMBL12938771 | 0.80 | HDAC1 (0.43) | HTR2AHTR2CNR3C1KCNH2CYP11B1 | |
| SCHEMBL21026002 | 0.78 | MCHR1 (0.53) | KCNH2 | |
| SCHEMBL7071662 | 0.77 | KMO (0.45) | HTR2AHTR2CNR3C1CYP11B1CYP11B2 | |
| SCHEMBL2627065 | 0.77 | TRPA1 (0.47) | NR3C1KCNH2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661406-B2 | Method for producing intermediate useful for synthesis of SGLT inhibitor | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2023-05-30 | — | — | US | disclosed |
| US-11661406-B2 | Method for producing intermediate useful for synthesis of SGLT inhibitor | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2023-05-30 | — | — | US | disclosed |
| US-20210292291-A1 | METHOD FOR PRODUCING INTERMEDIATE USEFUL FOR SYNTHESIS OF SGLT INHIBITOR | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-09-23 | — | — | US | disclosed |
| US-10889574-B2 | Method for producing diphenylmethane derivative | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-01-12 | — | — | US | disclosed |
| US-10640496-B2 | Method for producing diphenylmethane derivative | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2020-05-05 | — | — | US | disclosed |
| US-20190169174-A1 | METHOD FOR PRODUCING DIPHENYLMETHANE DERIVATIVE | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-06-06 | — | — | US | disclosed |
| US-9371303-B2 | Diphenylmethane derivatives as SGLT2 inhibitors | GREEN CROSS CORPORATION (KR) | 2016-06-21 | — | — | US | disclosed |
| US-20150152075-A1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | GREEN CROSS CORPORATION (KR) | 2015-06-04 | — | — | US | disclosed |
| US-9034921-B2 | Diphenylmethane derivatives as SGLT2 inhibitors | GREEN CROSS CORPORATION (KR) | 2015-05-19 | — | — | US | disclosed |
| US-8921412-B2 | C-aryl ansa SGLT2 inhibitors | GREEN CROSS CORPORATION (KR) | 2014-12-30 | — | — | US | disclosed |
| US-20140274918-A1 | METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES | GREEN CROSS CORPORATION (KR) | 2014-09-18 | — | — | US | disclosed |
| US-20140213642-A1 | NOVEL C-ARYL ANSA SGLT2 INHIBITORS | GREEN CROSS CORPORATION (KR) | 2014-07-31 | — | — | US | disclosed |
| US-20140088079-A1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | GREEN CROSS CORPORATION (KR) | 2014-03-27 | — | — | US | disclosed |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-7622491-B2 | Type 2 diabetes, atherosclerosis, cardiovascular disease, Syndrome X; carboxylic acids with dialkyldiether or thioether linking groups e.g. {4-[3-(2-Benzotriazol-2-yl-4-chloro-phenoxy)-propoxy]-phenyl}-acetic acid and {4-[3-(2-benzotriazol-2-yl-4-thiophen-2-yl-phenoxy)-propoxy]-phenyl}-acetic acid | METABOLEX INC. (US) | 2009-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169174-A1 | METHOD FOR PRODUCING DIPHENYLMETHANE DERIVATIVE | SLC5A2, SLC5A1, SLC2A1 | HTR2A 587/4885HTR2C 512/4885NR3C1 1957/4885 |
| US-20140088079-A1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | SLC5A2, SLC5A1, SLC2A8 | HTR2A 973/4885HTR2C 938/4885NR3C1 1305/4885 |
| US-20210292291-A1 | METHOD FOR PRODUCING INTERMEDIATE USEFUL FOR SYNTHESIS OF SGLT INHIBITOR | SLC5A2, SLC5A1, UGT2B7 | HTR2A 979/4885HTR2C 461/4885NR3C1 818/4885 |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | HTR2A 4692/4885HTR2C 4579/4885NR3C1 2043/4885 |
| US-11661406-B2 | Method for producing intermediate useful for synthesis of SGLT inhibitor | SLC5A2, SLC5A1, UGT2B7 | HTR2A 979/4885HTR2C 461/4885NR3C1 818/4885 |
| US-20140213642-A1 | NOVEL C-ARYL ANSA SGLT2 INHIBITORS | SLC5A2, SLC5A1, SLC2A1 | HTR2A 895/4885HTR2C 1393/4885NR3C1 1561/4885 |
| US-10640496-B2 | Method for producing diphenylmethane derivative | SLC5A2, SLC5A1, SLC2A1 | HTR2A 587/4885HTR2C 512/4885NR3C1 1957/4885 |
| US-10889574-B2 | Method for producing diphenylmethane derivative | SLC5A2, SLC5A1, SLC2A1 | HTR2A 587/4885HTR2C 512/4885NR3C1 1957/4885 |
| US-20150152075-A1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | SLC5A2, SLC5A1, SLC2A8 | HTR2A 938/4885HTR2C 898/4885NR3C1 1117/4885 |
| US-20140274918-A1 | METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES | SLC5A2, SLC5A1, SLC10A2 | HTR2A 942/4885HTR2C 1130/4885NR3C1 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.